ADC Therapeutics SA reports results for the quarter ended March 31 - Earnings Summary

ADC Therapeutics SA

14/05/2025 14:32

ADC Therapeutics SA ADCT.N reported a quarterly adjusted loss of 36 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -56 cents.  The mean expectation of six analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -56 cents to -33 cents per share.

Revenue rose 27.6% to $23.03 million from a year ago; analysts expected $17.71 million.

ADC Therapeutics SA's reported EPS for the quarter was a loss of 36 cents​.

The company reported a quarterly loss of $38.6 million.

ADC Therapeutics SA shares had fallen by 6.4% this quarter and lost 33.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 4.5% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."

Wall Street's median 12-month price target for ADC Therapeutics SA is $8.00

This summary was machine generated from LSEG data May 14 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.40
-0.36
Beat
Dec. 31 2024
-0.41
-0.29
Beat
Sep. 30 2024
-0.39
-0.42
Missed
Jun. 30 2024
-0.46
-0.38
Beat